MAIA Biotechnology, Inc.

MAIA Q2 2026 Earnings: Wider-Than-Expected Loss as Pre-Revenue Biotech Keeps Funding Clinical Work - Profit Guidance Range
https://www.dars.gov.et/ · 17 Oct 2026
MAIA Biotechnology hits enrollment milestones in Phase 2 and Phase 3 lung cancer trials
Dealroom · 07 Oct 2026
MAIA Biotechnology Achieves Patient Enrollment Milestones in Ongoing Phase 2 and Pivotal Phase 3 Clinical Trials in Non-Small Cell Lung Cancer
The Manila Times · 07 Oct 2026
Form 4 Maia Biotechnology Inc For: 7 October By Investing.com
Investing.com UK · 07 Oct 2026

Headlines from the last 30 days, linking to the original publishers. See all market news →

Disclaimer — PositoAI is a research and screening tool for educational and informational purposes. It is not investment advice or a recommendation to buy or sell any security or mutual fund. Scores and rankings are calculated by PositoAI's own method using publicly available data, which may be incomplete, delayed or inaccurate, and past performance does not indicate future results. AI summaries of company news may contain errors. PositoAI is not registered with the SEC, SEBI or any other regulatory authority. Please do your own research or consult a licensed financial advisor before investing.